Tags

Type your tag names separated by a space and hit enter

Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species.
Diagn Microbiol Infect Dis. 2013 Jan; 75(1):89-93.DM

Abstract

Ceftaroline, the bio-active form of parenterally administered ceftaroline fosamil, is a unique broad-spectrum cephalosporin with in vitro and in vivo activity against methicillin-resistant Staphylococcus aureus and was approved for clinical use by the United States Food and Drug Administration in October 2010. In over a year since ceftaroline fosamil approval, no widely used commercial susceptibility test system has added this new compound to its product, therefore requiring use of alternative agar diffusion methods for clinical microbiology laboratories that want to test clinical isolates for ceftaroline susceptibility. An alternative strategy of applying a surrogate β-lactam class marker agent was assessed here, using results from 14,902 organisms (2008-2010) sampled in the USA. Very high and acceptable accuracy (≥ 99.75%) was observed for predicting ceftaroline susceptibility as follows: 1) use of imipenem or meropenem minimum inhibitory concentrations (MICs) at ≤ 8 μg/mL (susceptible and intermediate categories) when testing S. aureus; 2) use of ceftriaxone MIC at ≤ 2 μg/mL (susceptible and intermediate categories) when testing Streptococcus pneumoniae as well as other streptococci (S. pyogenes and S. agalactiae); and 3) use of ceftriaxone, or cefepime, or ceftazidime at ≤ 2 μg/mL (susceptible category) when testing Haemophilus influenzae. Only when testing indicated Enterobacteriaceae species using ceftriaxone susceptibility results did the ceftaroline-nonsusceptible errors increase (4.11%). These presented analyses offer a validated surrogate marker strategy for ceftaroline susceptibility testing, pending development and validation by the commonly used automated systems and agar diffusion commercial methods.

Authors+Show Affiliations

JMI Laboratories, North Liberty, IA 52317, USA. ronald-jones@jmilabs.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23023107

Citation

Jones, Ronald N., et al. "Interim Susceptibility Testing for Ceftaroline, a New MRSA-active Cephalosporin: Selecting Potent Surrogate Β-lactam Markers to Predict Ceftaroline Activity Against Clinically Indicated Species." Diagnostic Microbiology and Infectious Disease, vol. 75, no. 1, 2013, pp. 89-93.
Jones RN, Flamm RK, Sader HS, et al. Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species. Diagn Microbiol Infect Dis. 2013;75(1):89-93.
Jones, R. N., Flamm, R. K., Sader, H. S., & Stilwell, M. G. (2013). Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species. Diagnostic Microbiology and Infectious Disease, 75(1), 89-93. https://doi.org/10.1016/j.diagmicrobio.2012.08.022
Jones RN, et al. Interim Susceptibility Testing for Ceftaroline, a New MRSA-active Cephalosporin: Selecting Potent Surrogate Β-lactam Markers to Predict Ceftaroline Activity Against Clinically Indicated Species. Diagn Microbiol Infect Dis. 2013;75(1):89-93. PubMed PMID: 23023107.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species. AU - Jones,Ronald N, AU - Flamm,Robert K, AU - Sader,Helio S, AU - Stilwell,Matthew G, Y1 - 2012/09/28/ PY - 2012/06/29/received PY - 2012/08/21/revised PY - 2012/08/21/accepted PY - 2012/10/2/entrez PY - 2012/10/2/pubmed PY - 2013/5/11/medline SP - 89 EP - 93 JF - Diagnostic microbiology and infectious disease JO - Diagn Microbiol Infect Dis VL - 75 IS - 1 N2 - Ceftaroline, the bio-active form of parenterally administered ceftaroline fosamil, is a unique broad-spectrum cephalosporin with in vitro and in vivo activity against methicillin-resistant Staphylococcus aureus and was approved for clinical use by the United States Food and Drug Administration in October 2010. In over a year since ceftaroline fosamil approval, no widely used commercial susceptibility test system has added this new compound to its product, therefore requiring use of alternative agar diffusion methods for clinical microbiology laboratories that want to test clinical isolates for ceftaroline susceptibility. An alternative strategy of applying a surrogate β-lactam class marker agent was assessed here, using results from 14,902 organisms (2008-2010) sampled in the USA. Very high and acceptable accuracy (≥ 99.75%) was observed for predicting ceftaroline susceptibility as follows: 1) use of imipenem or meropenem minimum inhibitory concentrations (MICs) at ≤ 8 μg/mL (susceptible and intermediate categories) when testing S. aureus; 2) use of ceftriaxone MIC at ≤ 2 μg/mL (susceptible and intermediate categories) when testing Streptococcus pneumoniae as well as other streptococci (S. pyogenes and S. agalactiae); and 3) use of ceftriaxone, or cefepime, or ceftazidime at ≤ 2 μg/mL (susceptible category) when testing Haemophilus influenzae. Only when testing indicated Enterobacteriaceae species using ceftriaxone susceptibility results did the ceftaroline-nonsusceptible errors increase (4.11%). These presented analyses offer a validated surrogate marker strategy for ceftaroline susceptibility testing, pending development and validation by the commonly used automated systems and agar diffusion commercial methods. SN - 1879-0070 UR - https://www.unboundmedicine.com/medline/citation/23023107/Interim_susceptibility_testing_for_ceftaroline_a_new_MRSA_active_cephalosporin:_selecting_potent_surrogate_β_lactam_markers_to_predict_ceftaroline_activity_against_clinically_indicated_species_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(12)00351-3 DB - PRIME DP - Unbound Medicine ER -